192 related articles for article (PubMed ID: 35241387)
21. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
Cahu X; Chevallier P; Clavert A; Suarez F; Michallet M; Vincent L; Vigouroux S; Blaise D; Mariette C; Bilger K; Robin M; Yakoub-Agha I; Peffault de Latour R; Mohty M
Bone Marrow Transplant; 2014 Jun; 49(6):756-60. PubMed ID: 24614840
[TBL] [Abstract][Full Text] [Related]
22. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
[TBL] [Abstract][Full Text] [Related]
24. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Tam CS; Nussenzveig RM; Popat U; Bueso-Ramos CE; Thomas DA; Cortes JA; Champlin RE; Ciurea SE; Manshouri T; Pierce SM; Kantarjian HM; Verstovsek S
Blood; 2008 Sep; 112(5):1628-37. PubMed ID: 18566326
[TBL] [Abstract][Full Text] [Related]
25. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
[TBL] [Abstract][Full Text] [Related]
26. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
[TBL] [Abstract][Full Text] [Related]
29. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
[TBL] [Abstract][Full Text] [Related]
30. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.
Mollard LM; Chauveau A; Boyer-Perrard F; Douet-Guilbert N; Houot R; Quintin-Roué I; Couturier MA; Dagorne A; Malou M; Le Calloch R; Luycx O; Thepot S; Hunault M; Guillerm G; Berthou C; Ugo V; Lippert É; Ianotto JC
Leuk Lymphoma; 2018 Dec; 59(12):2812-2820. PubMed ID: 29616837
[TBL] [Abstract][Full Text] [Related]
31. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernández-Boluda JC; Martínez-Cuadrón D; Pereira A; Rodríguez-Veiga R; Boluda B; Gil C; Casal-Marini S; Serrano J; Martínez-López J; Bergua J; Algarra L; Bernal T; López-Lorenzo JL; Colorado M; López A; Tormo M; Sayas MJ; Trigo F; López-Pavía M; Pérez-Simón JA; Lavilla-Rubira E; Rodríguez-Medina C; Rodríguez-Gutiérrez JI; Sanz-Caballer MA; Montesinos P;
Leuk Res; 2022 Apr; 115():106821. PubMed ID: 35286939
[TBL] [Abstract][Full Text] [Related]
32. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
Mannelli F; Guglielmelli P; Fazi P; Crea E; Piciocchi A; Vignetti M; Amadori S; Pane F; Venditti A; Vannucchi AM
Future Oncol; 2023 Jan; 19(2):103-111. PubMed ID: 36651780
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
Helbig G; Koclęga A; Woźniczka K; Kopera M; Kyrcz-Krzemień S
Pathol Oncol Res; 2018 Jul; 24(3):469-475. PubMed ID: 28660547
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.
Chen J; Wang K; Xiao Z; Xu Z
Ann Med; 2023 Dec; 55(1):348-360. PubMed ID: 36644935
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.
Davidson MB; Kennedy JA; Capo-Chichi JM; Shi Y; Xu W; Cheung V; Arruda A; Bankar A; Richard-Carpentier G; Chan S; Maze D; Minden MD; Schimmer AD; Schuh AC; Sibai H; Yee K; Tierens A; Viswabandya A; Gupta V
Blood Adv; 2024 Mar; 8(5):1281-1294. PubMed ID: 38170760
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia.
Aladag E; Aktimur SH; Aydın Ö; Demiroglu H; Buyukasik Y; Aksu S; Ozcebe OI; Haznedaroglu IC; Sayinalp N; Turgut M; Goker H
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):147-153. PubMed ID: 33451957
[TBL] [Abstract][Full Text] [Related]
37. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
38. Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phase.
Wang X; Rampal RK; Hu CS; Tripodi J; Farnoud N; Petersen B; Rossi MR; Patel M; McGovern E; Najfeld V; Iancu-Rubin C; Lu M; Davis A; Kremyanskaya M; Weinberg RS; Mascarenhas J; Hoffman R
JCI Insight; 2022 Apr; 7(8):. PubMed ID: 35259128
[TBL] [Abstract][Full Text] [Related]
39. Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program.
Solomon SR; Solh M; Jackson KC; Zhang X; Kent Holland H; Bashey A; Morris LE
Bone Marrow Transplant; 2020 Jan; 55(1):189-198. PubMed ID: 31527818
[TBL] [Abstract][Full Text] [Related]
40. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
